EULAR press releases

News of July 2021

2. Jul. 2021

EULAR Patient Research Partners participate in new EU research project HIPPOCRATES on Psoriatic Arthritis

Promoting early identification and improving outcomes for people with psoriatic arthritis

EULAR is one of 26 European research partners, including pharmaceutical companies, SME’s and patient organisations, to have joined forces to develop innovative personalised treatment options for people affected by psoriatic arthritis.   

News of June 2021

18. Jun. 2021

Empowering people with Inflammatory Arthritis

EULAR has released new recommendations on self-management for people with inflammatory arthritis.


Inflammatory arthritis is a group of conditions characterised by pain and swelling in the joints. This is caused by underlying inflammation, driven by the body’s immune system attacking its own tissues – sometimes called autoimmune disease. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. These each have their own definitions, and can affect different parts of the body, but they share the common feature of inflammation and joint symptoms.

10. Jun. 2021

EULAR Meritorious Service Awards 2021: Professor Maxime Dougados and Professor Josef Smolen named recipients

The European Alliance of Associations for Rheumatology, EULAR, named Maxime Dougados and Josef Smolen as the winners of the 2021 EULAR Meritorious Service Awards.

9. Jun. 2021

Incoming EULAR President Prof Annamaria Iagnocco Focuses on inclusion, cutting-edge education, and the new EULAR Strategy

EULAR welcomes Prof Annamaria Iagnocco, Turin, Italy, as the new president of the organisation, succeeding Prof Iain McInnes, Glasgow, UK. Prof Iagnocco will focus on inclusion and diversity and will set the milestones for the future EULAR strategy from 2023.

7. Jun. 2021

Improving uniformity and Quality of Care for people undergoing Intra-Articular Injection

EULAR releases new recommendations on the use of intra-articular therapies

Intra-articular therapies (IAT) are frequently used to treat joint conditions such as gout, rheumatoid arthritis, or osteoarthritis. The procedure involves inserting a needle into the space between the bones of the joint to deliver a drug. The types of injectables used in IAT techniques vary, from steroids to radiopharmaceuticals.

5. Jun. 2021

Understanding the impact of patient empowerment and remote management in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. In people with RA, low empowerment is associated with worse health. Interventions to improve empowerment may include helping people to master their pain, increase physical function, and improve physical activity. Remote technologies to support patient-reported self-assessment may help improve patient empowerment and disease management.

4. Jun. 2021

Decline in excess risk of dementia and heart failure in patients with Rheumatoid Arthritis

Data released at the 2021 EULAR congress show a substantial decline in the risk of both dementia and heart failure in people with rheumatoid arthritis (RA) onset in the 2000s as compared to 1980s – coinciding with the advent of novel biologic treatments for RA.

4. Jun. 2021

Impact of a national tender system on biologic and targeted drug costs in Norway

Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have caused a shift in the treatment of patients with inflammatory joint disorders, and remission is now attainable. But the high cost of these drugs has caused restrictions on their use and prescription, contributing to inequality of care worldwide. An annual tender system was introduced in 2008 in Norway to reduce the costs of these drugs.

4. Jun. 2021

Baseline medication use is associated with COVID-19 severity in people with Rheumatic Diseases

COVID-19 is the disease caused by SARS-CoV-2 infection. It has been suggested that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) may dampen the inflammatory response in COVID-19, perhaps leading to a less severe clinical course of the infection. However, the way some antirheumatic drugs work might impair the body’s natural immune defence against viruses. Two abstracts presented at EULAR 2021 show people taking rituximab or a class of drugs called janus kinase inhibitors (JAKi) have worse COVID-19 severity compared to people taking tumour necrosis factor inhibitors (TNFi). These data from two large registry initiatives highlight the urgent need for strategies to manage the risk in people taking antirheumatic drugs, such as identifying optimal timing for vaccination.

4. Jun. 2021

Pregnancy outcomes are affected by both maternal and paternal Inflammatory Disease

Data presented at the 2021 EULAR congress show women with rheumatoid arthritis (RA) are at increased risks of adverse pregnancy outcomes, especially pre-term birth and babies small for gestational age. For the first time, it has also been shown that the partners of men with inflammatory arthritis have a lower rate of live births, and are more likely to suffer a miscarriage. However, the link between disease activity, type and timing of antirheumatic treatment, and the risk of these outcomes remains unclear.

4. Jun. 2021

There is an unacceptable delay to diagnosis in Axial Spondyloarthritis

The current delay to diagnosis from symptom onset represents one of the greatest challenges in axial spondyloarthritis (axSpA) – a type of inflammatory arthritis affecting the back. Research shows an average delay of around 7 years – and up to 15 years in some cases – during which time the condition can progress and lead to irreversible damage. Data indicates that women wait longer than men for a diagnosis, and there has been very limited progress in reducing the time to diagnosis. This delay has a hugely detrimental impact on a person’s quality of life. Because the disease frequently has early onset, individuals are left untreated – or with incorrectly treated symptoms – at a formative period in their life course.

4. Jun. 2021

An increase in Giant Cell Arteritis cases associated with peaks in COVID-19 prevalence

Giant cell arteritis (GCA) is an inflammatory disease that affects the arteries, often causing headaches, jaw pain, and vision problems. The precise cause is not known, but infection is thought to play a role. Immediately following the first wave of the COVID-19 pandemic, the number of GCA diagnoses noticeably increased at the Royal National Hospital for Rheumatic Diseases in Bath, United Kingdom (UK). Furthermore, there was an increase in the proportion of patients with visual complications. The finding is important for understanding the underlying disease mechanisms in GCA, and supports the idea that viral infection could be involved. It also has implications for the provision of local services.

4. Jun. 2021

Genetic variant link with long-term incidence of Interstitial Lung Disease in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. Up to 10% of people with RA are affected by interstitial lung disease (ILD) during their lifetime, and ILD is one of the leading causes of death in patients with RA. Data presented at the 2021 EULAR congress report findings from a longitudinal study showing that people with MUC5B gene variant have a considerable lifetime risk of ILD, and that this gene variant contributes to increased morbidity. These findings have clinical implications for improving identification of people with RA who are at high risk for developing ILD.

3. Jun. 2021

COVID-19 morbidity and mortality in people with Rheumatic Diseases: New data and insights from Spain and Sweden

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is of particular concern for people with inflammatory diseases, and there are concerns that these people may be at higher risk and have poorer outcomes. However, at present the implications remain poorly understood. Population-based data from Spain show individuals with rheumatoid arthritis (RA) had an increased risk of COVID-19 diagnosis and hospitalization compared to the general population. Similarly, data from the ARTIS database in Sweden show risks of severe COVID-19 were increased among people with inflammatory joint diseases.

3. Jun. 2021

The true spread of SARS-COV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases

The true prevalence of COVID-19 is still unknown due to the high proportion of subclinical infection. Measuring seroprevalence may be crucial to improve knowledge about the impact of COVID-19 in rheumatic patients. Data shared at the 2021 EULAR congress highlight that the spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases, but consistent with healthy population.

3. Jun. 2021

Inflammation of the eye after drug withdrawal in children with Arthritis

Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness. The majority of children develop uveitis within the first 2 years after arthritis symptom onset, but it can continue into adulthood. This is the first prospective study to analysed uveitis risk after drug withdrawal, and found that uveitis relapses are common. Rheumatologists and ophthalmologists should be aware and should plan for uveitis screening after drug withdrawal.

3. Jun. 2021

Elderly patients are not at increased risk of serious infections with new disease-modifying Antirheumatic drugs compared to conventional Synthetic treatments

Elderly people with rheumatoid arthritis (RA) are generally at increased risk of serious infections. At the same time, some anti-rheumatic treatments have been associated with a higher serious infection risk, but the extent to which older people are exposed to higher risks with some newer classes of therapy is an open question. Results of this study suggest that treatment with new classes of drugs is not associated with an increased risk of serious infection in elderly patients above 70 years of age.

3. Jun. 2021

Treatment with Tumour Necrosis Factor Inhibitors may slow disease progression in people with Spondyloarthritis

Sacroiliitis is an inflammation of the sacroiliac joints, situated where the lower spine and pelvis connect. Sacroiliitis is linked to the disease axial spondyloarthritis (axSpA) and visible on X-ray. Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis, which might also have an impact on the function in patients with axSpA. Recent data show that tumour necrosis factor inhibitors (TNFi) might slow spinal progression when started earlier and taken for longer. However, the question of whether they also have such an effect on radiographic progression in sacroiliac joints is still unclear.

2. Jun. 2021

First trial of Faecal Microbiota Transplantation for people with active Peripheral Psoriatic Arthritis shows no advantage

Results of the first trial of its kind presented at EULAR 2021

Targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel therapeutic option for people with extra-intestinal inflammatory diseases – although the link is yet to be established. In this first interventional randomised controlled trial of FMT in immune-mediated arthritis, transplantation was inferior to sham in treating active peripheral psoriatic arthritis.

2. Jun. 2021

Passive smoking and air pollution – links to Arthritis development and poor response to therapy

New data shared at the 2021 EULAR congress

There is increasing evidence that environmental air pollution is associated with people developing inflammatory arthritis. At the 2021 EULAR congress, a large population-based study of French women reports passive exposure to smoking during childhood or adulthood increases the risk of developing rheumatoid arthritis (RA). A second study in Italy found that air pollution also has an impact – with air pollution levels showing an association with failure of biologic therapy.

2. Jun. 2021

EULAR is working to accelerate Gender-Equitable career advancement in Academic Rheumatology

A framework and EULAR task force on gender equity in academic rheumatology

A growing number of professional societies in clinical and medical disciplines are investigating evidence, making recommendations, and taking action to advance gender equity.

News of April 2021

12. Apr. 2021

Points to consider for studies of work participation in people with Inflammatory Arthritis

A new publication from EULAR highlights the issues around designing, analysing, and reporting of studies using work participation as an outcome measurement.

Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body’s immune system attacks its own tissues and causes inflammation. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Inflammatory arthritis often affects people of working age, and can impact their employment. Work participation is often lower for people with inflammatory arthritis than the general population.

News of February 2021

17. Feb. 2021

EULAR: Supporting research at the Nexus of Science and the Clinic

EULAR launches new service to provide expert research advice for translational science investigators across Europe who want to develop solutions to the unmet needs of people with rheumatic and musculoskeletal diseases (RMDs).

12. Feb. 2021

Repurposing Rheumatology drugs for COVID-19

EULAR has released new points to consider on the use of immunomodulatory drugs in the fight against severe COVID-19

COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. Since it emerged at the end of 2019, this virus has caused a global pandemic. COVID-19 can be mild, or even without symptoms at all. But it can also cause severe disease, leading to respiratory problems, organ failure, and death. Research on the immune mechanisms involved in people with severe COVID-19 has shown that they have widespread inflammation. Early on in the pandemic, several immunomodulatory anti-inflammatory treatments commonly used in people with rheumatic and musculoskeletal diseases (RMDs) were proposed as possible options for people with severe COVID-19.

5. Feb. 2021

Recognising young people’s perspectives in Inflammatory Arthritis

A new EULAR study shows that young people with arthritis need new ways to measure their function that take into account their age and lifestyle

Inflammatory arthritis is the name of a group of diseases that cause joint pain and swelling. This happens because the body’s immune system attacks its own tissues and causes inflammation. Types of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Although they may be thought of as older people’s conditions, these diseases can affect people at any age. Traditional patient-reported outcome measures (PROMs) record things like walking ability, which may not be relevant for young people early in their disease.

2. Feb. 2021

Characteristics associated with COVID-19-related death in people with Rheumatic and Musculoskeletal Diseases (RMDs)

New research examines the factors associated with COVID-19-related death in a large real-world dataset of people with rheumatic and musculoskeletal diseases

News of January 2021

1. Jan. 2021

EULAR announces 'European Alliance of Associations for Rheumatology’ as its new name

EULAR is pleased to announce the formal renaming of the organisation as ‘European Alliance of Associations for Rheumatology’, changing from ‘European League Against Rheumatism’, following the implementation of new EULAR Statutes, approved on 3 June 2020 by the General Assembly, entering into force on 1 January 2021.

News of December 2020

11. Dec. 2020

New: Core Data Set for Pregnancy Registries

EULAR established the first consensus-based core data set for prospective pregnancy registries in rheumatology. This will increase the knowledge about women with inflammatory rheumatic diseases (IRD) during pregnancy.

News of November 2020

19. Nov. 2020

EULAR: Improving research on rheumatic and musculoskeletal diseases across Europe together

EULAR launches new service to provide expert research advice for investigators across Europe who study ways to improve the lives of people with rheumatic and musculoskeletal diseases.

News of October 2020

12. Oct. 2020

EULAR: Workplace exclusion of people with arthritis compounded by COVID-19

The COVID pandemic has compounded the risks facing this vulnerable group and, with Europe facing the growing challenges of an ageing population and workforce, it is vital that the EU addresses the hidden costs of workplace exclusion for people suffering one of the over two hundred diseases under the RMD umbrella.

8. Oct. 2020

Unifying Terminology for Difficult-to-Treat Rheumatoid Arthritis

EULAR proposes a definition for difficult-to-treat RA in the hope of supporting clinical practice, trials, and research in the area.

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. A significant proportion of people with rheumatoid arthritis (RA) still have symptoms despite receiving treatment according to the current management recommendations. These people can be considered to have ’difficult-to-treat RA’. However, there is no uniform terminology or definitions to decide when this applies. The concept is referred to by many different terms, including severe, refractory, drug-resistant, or established RA. EULAR prefer the term ‘difficult-to-treat’ because it best capture the possible clinical scenarios. Being clear on terminology is important because people with difficult-to-treat RA may require a different approach.

News of September 2020

4. Sep. 2020

The EULAR School of Rheumatology wins Awards for excellence in learning

EULAR, a leader in innovative education in rheumatology, wins a coveted Brandon Hall Group awards for Excellence in Learning: Silver for Best Learning Team and bronze for Best Strategy for a Corporate Learning University.

News of August 2020

19. Aug. 2020

Osteoarthritis: Conservative Therapy Programme delays need for knee and hip joint replacement surgery

With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.

18. Aug. 2020

EULAR: New best practice rheumatology training guidelines established by EULAR

Expert panel’s recommendations aim to further harmonise and improve rheumatology training and patient care in Europe. 

12. Aug. 2020

Amputations of feet, toes and other body parts. The Combination of Diabetes and Gout significantly increases the risk

Compared to the average population, people suffering from both gout and diabetes have a 25 times higher risk of requiring an amputation of peripheral limbs such as feet, toes or lower legs.

News of July 2020

30. Jul. 2020

EULAR: Significant Increase For Impact Factor Of Annals Of The Rheumatic Diseases (ARD), The EULAR Journal, reflects rapidly improving quality of Rheumatology Research

The journal of the European League Against Rheumatism, ARD, has reached a new record, arriving at an impact factor of 16.102 this year, up from 14.299 last year.

27. Jul. 2020

Ankylosing Spondylitis (AS): Becoming a mother despite having a rheumatic disease? Study of Infants and Young Children Shows that Offspring Develop Normally

Women with ankylosing spondylitis (AS) can have children despite their rheumatic disease. But how do their children develop? A recent South Korean study has now come to the conclusion that the growth and development of infants and young children of mothers with AS are comparable to those of other mothers. 

21. Jul. 2020

EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19 associated Cytokine Storm related hospital mortality by 65%

New study demonstrates that a widely available immunosuppressant used for treatment of RMDs dramatically improves patient outcomes when compared to supportive care only.

7. Jul. 2020

Rheumatoid Arthritis Patients under Treatment with Methotrexate: Immunosuppressant Treatment does not confirm negative Effects on Lung Conditions in Patients

Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

News of June 2020

17. Jun. 2020

Early and intensive Treatment of rheumatoid Arthritis reduces Fatigue

Better quality of life for people with rheumatic and musculoskeletal diseases

9. Jun. 2020

European League Against Rheumatism (Eular) advocates the Deployment Of other Health Care Professionals – New Study confirms their Effectiveness

Insufficient health care for people with rheumatic diseases in Germany

9. Jun. 2020

New: Rheumatic Disease in the Context of COVID-19

The European League Against Rheumatism (EULAR) has published new provisional recommendations in response to the SARS-CoV-2 (COVID-19) pandemic

9. Jun. 2020

The European League Against Rheumatism, EULAR, launches Virtual Research Centre

Improving the lives of people with rheumatic and musculoskeletal diseases through research.

5. Jun. 2020

Thrombosis Risk particularly high for people suffering from rheumatic and musculoskeletal disease activity

Vigilance for thrombosis during the treatment of people with arthritis is particularly recommended. Moreover, maintaining therapies to keep disease activity under control is vital.

4. Jun. 2020

Rheumatic pain: increasingly more patients taking opioids; European league against rheumatism (EULAR) indicates the risk due to addiction

Fentanyl, tramadol or tilidine: New European figures show that even in Europe increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases.

3. Jun. 2020

Study on COVID-19 in the Context of Rheumatic and Musculoskeletal Diseases Provides Reassurance to Patients on Immunosuppressive Medications

The results of the study will be presented in an online press conference in the context of the EULAR Congress on 3 June 2020.

News of May 2020

27. May. 2020

Update: EULAR Recommendations of the Pharmacological Treatment of Psoriatic Arthritis

The recommendations are designed to help physicians and health professionals choose the right drug for people with psoriatic arthritis (PsA). Due to the arrival of new drugs, the recommendations have been updated since their last update in 2015.

8. May. 2020

New: EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

These points to consider are designed to raise awareness and to assist rheumatologists to improve the diagnosis and the management of patients who develop side effects from checkpoint inhibitor drugs: rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of cancer patients receiving immune checkpoint inhibitors (ICI).

News of April 2020

29. Apr. 2020

New: Update of the joint EULAR/ERA-EDTA recommendations for the management of lupus nephritis

EULAR has published updated recommendations for the management of lupus nephritis. The update presents recent evidence on the use of certain drugs, disease monitoring and treatment targets.

27. Apr. 2020

EULAR: Hydroxychloroquine use in lupus patients ‘does not seem to prevent COVID-19’

ARD publishes first information regarding the impact of COVID-19 on patients with Systemic Lupus Erythematous already taking anti-malarial drug, Hydroxychloroquine.  

17. Apr. 2020

EULAR encourages Europe to include expert view in shortages question

EULAR welcomes and supports the efforts to address shortages of medicines, including hydroxychloroquine, on the European market.

3. Apr. 2020

EULAR releases first reports on arthritis and COVID-19 in Italy

EULAR, has published two letters this week containing findings from COVID-19 cases concerning those suffering from rheumatic and musculoskeletal diseases in Italy.  

3. Apr. 2020

EULAR President: Application of anti-malarials to tackle COVID-19 raises vital issues for rheumatic disease community in Europe

EULAR, welcomes global efforts aimed at increasing the information base around the potential for anti-malarial drugs in the treatment of COVID-19.

1. Apr. 2020

EULAR: Points to consider when using ‘big data’

EULAR, showcases its points to consider when using big data and computer-aided research methods in rheumatic and musculoskeletal diseases. The points are intended to provide a framework for rheumatologists, health professionals, patients and other stakeholders about how best to use big data and artificial intelligence to help answer important research questions.

1. Apr. 2020

EULAR releases recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

EULAR, has published recommendations for the management of patients with Sjögren’s syndrome with topical and systemic therapies. The therapeutic management of Sjögren’s syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. 

1. Apr. 2020

2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis

A EULAR task force of rheumatologists, health professionals and patients formulated three overarching principles and eight recommendations for the role of nurses in chronic inflammatory arthritis (CIA) care. 

1. Apr. 2020

EULAR publishes 2018 update of evidence-based recommendations for diagnosis of gout

Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed and its management remains suboptimal, despite effective treatments.

News of March 2020

27. Mar. 2020

EULAR launches COVID-19 rheumatic and musculoskeletal diseases reporting database as part of Global Rheumatology Alliance

EULAR launches a European paediatric and adult database to monitor and report outcomes of COVID-19 occurring in patients with rheumatic and musculoskeletal diseases with the support of the Global Rheumatology Alliance.

25. Mar. 2020

2018 update of the EULAR recommendations for the management of large vessel vasculitis

A EULAR task force conducted a systematic literature review of recently published clinical trials and cohort analyses and sought opinion from 20 experts from 13 countries. 

News of January 2020

28. Jan. 2020

EULAR Recommendations: RA management / Update 2019

EULAR has announced updated recommendations for the management of patients with rheumatoid arthritis (RA) in its newly published paper, ‘EULAR Recommendations for the management of rheumatoid arthritis with synthetic and disease-modifying antirheumatic drugs: 2019 update’.

News of November 2019

28. Nov. 2019

2019 update of EULAR Recommendations for vaccination in adult patients

25 November, 2019, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published updated recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). 

News of October 2019

28. Oct. 2019

Press release: Core competences, HPRs in rheumatology

EULAR has published its first set of recommendations for the generic core competences of health professionals in rheumatology, with specific reference to nurses, physical therapists and occupational therapists.

News of July 2019

2. Jul. 2019

New EULAR President receives CBE and starts two-year term

Professor Iain McInnes has started his term in office as president of the European League Against Rheumatism

News of June 2019

7. Jun. 2019

EULAR Press Release: Patients with Sjögren's Syndrome in Europe

Patient's with Sjögren's Syndrome gather to take their destiny into their own hands. 

News of May 2019

27. May. 2019

EULAR press release: Antiphospholipid syndrome in adults

The European League Against Rheumatism, EULAR, has published a set of recommendations for the management of antiphospholipid syndrome in adults

News of April 2019

4. Apr. 2019

New: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

4th April, 2019, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published an update to a set of recommendations for the management of systemic lupus erythematosus. 

4. Apr. 2019

EULAR PARE Engagement Programme Press Release 2019

EULAR aims to engage with and support national organisations by providing a EULAR representative or speaker at their events.

News of October 2018

12. Oct. 2018

World Arthritis Day 2018: The press release

On World Arthritis Day ‘Don’t Delay, Connect Today’ Campaign educates on the importance of early diagnosis of rheumatic diseases.

7. Oct. 2018

EULAR Brussels Conference 2018

Get ready to join the EULAR Brussels Conference over livestream on Tuesday, 9 October!

News of July 2018

13. Jul. 2018

EULAR Recommendations on the effect of exercise and physical activity promotion in people with rheumatoid arthritis, spondyloarthritis and osteoarthritis

12th July, 2018, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published a set of recommendations for health professionals regarding physical activity in people with rheumatoid arthritis, spondyloarthritis and osteoarthritis. The recommendations report in detail on the meta-analysis that was performed to answer the question on the effectiveness of physical activity interventions.

News of June 2018

15. Jun. 2018

Press Release: Studies provide new insights into the role of sleep in chronic pain

Amsterdam, The Netherlands, 15 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into the role of sleep in chronic pain. The first study demonstrates a predictive role of sleep problems for chronic pain1 and the second provides insight into chronic pain and sleep in adolescents.

15. Jun. 2018

Press Release: Study suggests siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome

Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate an increased risk of acute coronary syndrome (ACS) in siblings of individuals with rheumatoid arthritis (RA), suggesting shared susceptibility between the two diseases.

15. Jun. 2018

Press Release: Obesity in women and current smoking in men predict lack of remission in early rheumatoid arthritis

Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis (RA) within a year.

15. Jun. 2018

Press Release: Gout in the elderly linked to higher risk of dementia

Amsterdam, The Netherlands, 15 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest that gout is associated with a 17-20% higher risk of dementia in the elderly.

15. Jun. 2018

Press Release: Gum disease may be a key initiator of rheumatoid arthritis related autoimmunity

Amsterdam, The Netherlands, 15 June 2018: The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrates increased levels of gum disease, and disease-causing bacteria, in individuals at risk of rheumatoid arthritis (RA).

15. Jun. 2018

Press Release: Rates of depression and anxiety may correlate with disease activity in early rheumatioid arthritis

Amsterdam, The Netherlands, 15 June 2018: The results of a study to be presented at the Annual European Congress of Rheumatology (EULAR 2018) suggest that rates of anxiety and depression in patients with rheumatoid arthritis correlate with measures of disease activity over the first year following diagnosis.

15. Jun. 2018

Press Release: Obesity in childhood and adulthood shown to increase risk of knee and hip osteoarthritis

Amsterdam, The Netherlands, 15 June 2018: The results of a study to be presented at the Annual European Congress of Rheumatology (EULAR 2018) suggest childhood and adult obesity increase the risk of developing hip osteoarthritis (OA) and knee OA but not hand OA.

14. Jun. 2018

Press Release: Onset of depressive symptoms significantly associated with disease severity in patients with knee osteoarthritis

Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that among individuals with radiographic knee osteoarthritis (OA), decreased physical performance and greater structural disease severity are associated with a higher risk of experiencing depressive symptoms.

14. Jun. 2018

Press Release: Significant increase in self-harm attempts following ankylosing spondylitis diagnosis

Amsterdam, The Netherlands, 14 June 2018: The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate a significantly increased rate of self-harm attempts in inflammatory arthritis (IA), particularly following a diagnosis of Ankylosing Spondylitis (AS).

14. Jun. 2018

Press Release: Clinical advances in systemic lupus erythematosus

Amsterdam, The Netherlands, 14 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate exciting advances for individuals suffering from systemic lupus erythematosus (SLE).1,2 The first is a phase II clinical study of a promising oral treatment, baricitinib.1 The second demonstrates the effective use of the shingles vaccine* in SLE patients who are particularly prone to this infection.

14. Jun. 2018

Press Release: Rheumatoid arthritis in pregnancy associated with low birth weight and premature birth

Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that pregnancies in women with rheumatoid arthritis are associated with premature delivery and low birth weight.

14. Jun. 2018

Press Release: Youth-R-Coach: A peer-to-peer program for young people suffering with chronic disease

Amsterdam, The Netherlands, 14 June 2018: The details of a youth project presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate how, by empowering patients to become ‘experts-by-experience’, young people can give support to peers as well as provide insights into living with a chronic illness as a young person.

14. Jun. 2018

Press Release: Daily text message may improve adherence and treatment outcomes in patients with gout

Amsterdam, The Netherlands, 14 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate significant improvements in adherence and clinical outcomes in gout patients who received a daily text message to remind them to take allopurinol.

14. Jun. 2018

Press Release: Combining NSAIDs and TNF inhibitors may reduce radiographic progression in ankylosing spondylitis

Amsterdam, The Netherlands, 14 June 2018: The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years.

14. Jun. 2018

Press Release: One year anniversary: EULAR Campaign

Amsterdam, The Netherlands, 14 June 2018: The European League Against Rheumatism (EULAR) today celebrated one year since the launch of its campaign, ‘Don’t Delay, Connect Today’, which was launched in June 2017 in Madrid, Spain. Now active in over twenty countries in Europe, and with more countries set to launch the campaign in the second half of the year, ‘Don’t Delay, Connect Today’ is gaining impact across all audiences, including at the political level in Europe.

13. Jun. 2018

Press Release: No difference in malignancy rates seen between tocilizumab and TNF inhibitors in patients with rheumatoid arthritis

Amsterdam, The Netherlands, 13 June 2018: The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi).

13. Jun. 2018

Press Release: Early, intensive treatment of rheumatoid arthritis provides long-term benefits and may normalise mortality rates

Amsterdam, The Netherlands, 13 June 2018: The results of a 23-year, follow-up study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest early, intensive treatment of rheumatoid arthritis has long-term benefits including the normalisation of mortality to levels consistent with the general population.

13. Jun. 2018

Press Release: Zoledronic acid shows no effect on knee pain or bone marrow lesions in knee osteoarthritis after two years

Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease.

13. Jun. 2018

Press Release: Canakinumab shown to reduce rates of gout in atherosclerosis by more than half

Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.

13. Jun. 2018

Press Release: New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)

Amsterdam, The Netherlands, 13 June 2018: The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).

13. Jun. 2018

Press Release: Launch of the EULAR Strategy 2018–2023

Amsterdam, The Netherlands, 13th June 2018: The European League Against Rheumatism (EULAR) has today presented its five-year strategy for the period 2018-2023 at the Annual European Congress of Rheumatology 2018. The strategy is the third strategic cycle in developing excellence in rheumatology in six areas of focus: Education, the annual congress, quality of care, research, advocacy and the internal organisation of EULAR.

13. Jun. 2018

Press Release: Gene signatures and biomarkers predict onset of rheumatoid arthritis in at-risk individuals

Amsterdam, The Netherlands, 13 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into molecular changes prior to the onset of arthritis which could inform future novel diagnostics and early therapeutic interventions.

13. Jun. 2018

Press Release: Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010

Amsterdam, The Netherlands, 13 June 2018: The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) investigate joint replacement procedures in rheumatoid arthritis (RA) patients.1,2 The first study demonstrates that joint replacement procedures have significantly reduced in RA patients in the past decade1 and the second investigates the impact of biologic therapies on this change using the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis (BSRBR/RA).

13. Jun. 2018

Press Release: NSAIDs shown to have casual role in cardiovascular risk of patients with osteoarthritis

Amsterdam, The Netherlands, 13 June 2018: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest that over two thirds of the increased cardiovascular risk associated with osteoarthritis is linked to the use of non-steroidal anti-inflammatory drugs (NSAIDs).

13. Jun. 2018

EULAR School of Rheumatology: Launch of online 'learning landscape' and new educational offers

The EULAR School of Rheumatology membership for EUR 30 per annum provides access to the latest learning enviornment and content in rheumatology.

News of May 2018

14. May. 2018

New: EULAR Recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis

14th May, 2018, Kilchberg, Switzerland – The European League Against Rheumatism, EULAR, has published a set of recommendations, designed to help health professionals implement approaches to pain management in inflammatory arthritis and osteoarthritis patients. The aim is to reduce pain and the burden on the individual and society.

News of April 2018

17. Apr. 2018

Press release: EULAR Recommendations for the management of Behҫet’s syndrome

EULAR has published a set of recommendations, which look at the management of Behçet’s syndrome.

News of January 2018

29. Jan. 2018

Press Release: EULAR Recommendations for the use of imaging in large vessel vasculitis in clinical practise

A EULAR task force has formulated 12 recommendations which have been published in its journal, The Annals of Rheumatic Diseases, the leading scientific journal in rheumatology with an impact factor of 12.811.

News of December 2017

7. Dec. 2017

Press release: EULAR Recommendations

Actively optimising patient care in rheumatism: Contribution to and dissemination of key scientific findings in rheumatology are set out in the EULAR Recommendations – and translated into lay versions as well as local languages across Europe

News of October 2017

17. Oct. 2017

Press release: Investment beyond 2020

EULAR has called on the European Commission to maintain the EU’s position as global leader in health research. This includes continuing investment in research and developing a forward-looking agenda beyond the current research framework programme, Horizon 2020.

News of July 2017

6. Jul. 2017

EULAR School of Rheumatology Launch A 'Benefit to Humanity'

New ‘one roof structure’ for EULAR educational offerings, services and products gives international rheumatology community access to cutting-edge continued professional development.

5. Jul. 2017

New Editor for Annals of the Rheumatic Diseases

BMJ, a leading healthcare knowledge provider, is pleased to announce Josef Smolen as the new editor of Annals of the Rheumatic Diseases (ARD).

ARD is the top ranked journal in the field of rheumatology with an impact factor of 12.811.

News of June 2017

26. Jun. 2017

EULAR contributes 70 years to the field of RMDs

EULAR has released a press release to international media circles in celebration of its 70th anniversary.

Read the text and comments from EULAR President Prof. Gerd Burmester and President-elect Prof. Johannes Bijlsma.

22. Jun. 2017

EULAR Campaign: Don't Delay, Connect Today

The EULAR Campaign, Don't Delay, Connect Today, encompasses the three pillars of the association, scientific, health professionals and patient organisations. It was launched in Madrid, Spain, in mid-June.

Find information toolkits on the dedicated webpage, watch the video and get involved!

14. Jun. 2017

POSTMENOPAUSAL WOMEN AT RISK OF FRACTURES COULD BE IDENTIFIED THROUGH GENETIC PROFILING

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed for the first time that genetic markers, identified in previous research as being linked to the development of osteoporosis, are also associated with the risk of fragility fractures in postmenopausal women.

14. Jun. 2017

NEW STUDY SHOWS FOR FIRST TIME LINK BETWEEN PASSIVE SMOKING IN CHILDHOOD AND RHEUMATOID ARTHRITIS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference confirmed the link between active smoking and the risk of developing rheumatoid arthritis (RA). However, interestingly, it also suggested for the first time that in smokers, exposure to tobacco early in life through passive smoking in childhood significantly increased this risk.

14. Jun. 2017

NEW RELAPSE PREDICTION TOOL REDUCES COST OF RHEUMATOID ARTHRITIS TREATMENT

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have shown that the combined use of two measurements to accurately predict the risk of relapse in patients with rheumatoid arthritis (RA) allows successful dose reduction (tapering) of their disease modifying anti-rheumatic drugs (DMARDs). This in turn increases the cost-effectiveness of each DMARD treatment.

14. Jun. 2017

NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).

14. Jun. 2017

GENES EXPLAIN HIGHER PREVALENCE OF CARDIOVASCULAR DISEASE IN CHRONIC IMMUNE MEDIATED INFLAMMATORY DISEASE PATIENTS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 represent an important step towards characterising the genetic basis of cardiovascular disease (CVD) risk in chronic immune-mediated inflammatory diseases (IMID).

14. Jun. 2017

EXCESS RISK OF CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS DECREASED SINCE START OF 21ST CENTURY

The results of a meta-analysis presented for the first time today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that the excess risk of cardiovascular events in rheumatoid arthritis (RA) patients relative to the general population has significantly decreased since the year 2000.

14. Jun. 2017

EDUCATION FOR PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES AND EMPLOYERS CAN IMPROVE ABILITY TO WORK

The results of an educational programme implemented by the Galician Rheumatology League (LRG), presented today at the Annual European Congress of Rheumatology (EULAR) 2017, showed that providing education and advice to people with rheumatic and musculoskeletal disease (RMD) and their employers can make a significant difference to the ability to work.

14. Jun. 2017

BIOSIMILAR CONCERNS OF RHEUMATOLOGY PATIENTS BEING ADDRESSED BY NATIONAL PROGRAMME

To address the fear and insecurity expressed by rheumatology patients on being switched from a biologic to a biosimilar treatment for their arthritis, the Danish Rheumatism Association has participated in a national programme designed to ensure patients received independent information about biosimilars, along with closer monitoring of prescriptions to provide reassurance about their safety. The results of this initiative were presented today at the Annual European Congress of Rheumatology (EULAR) 2017.

14. Jun. 2017

PERSISTENT PAIN SHOWS UP INEFFICIENCY OF CURRENT PSORIATIC ARTHRITIS (PsA) TREATMENT

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have highlighted limitations in the current treatment of patients with Psoriatic Arthritis (PsA).

14. Jun. 2017

NURSES CRUCIAL IN IMPROVING UPTAKE OF POTENTIALLY LIFE-SAVING VACCINE IN VULNERABLE RHEUMATIC PATIENTS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that implementing a vaccination programme run by nursing staff dramatically improves pneumococcal vaccination coverage among vulnerable patients with chronic inflammatory rheumatic diseases.

14. Jun. 2017

NEW BLOOD TEST DETECTS STROKE AND HEART ATTACK RISK IN LUPUS PATIENTS WITH NO CARDIOVASCULAR SYMPTOMS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference have shown that a specific biomarker detected in the blood of lupus patients with no symptoms of cardiovascular disease (CVD), thought to be at low risk of CVD based on traditional risk factors, is associated with the presence of atherosclerosis.

14. Jun. 2017

LOW-DOSE CT SCANNING IMPROVES ASSESSMENT OF ANKYLOSING SPONDYLITIS PATIENTS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 showed that low dose computed tomography (LD-CT) is more sensitive than conventional radiographs (X-rays) in the monitoring of disease progression in patients with Ankylosing Spondylitis (AS).

14. Jun. 2017

COGNITIVE BEHAVIOUR THERAPY (CBT) SIGNIFICANTLY REDUCED DEPRESSION AND ANXIETY IN CHRONIC PAIN PATIENTS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 has shown that Acceptance and Commitment Therapy, a form of cognitive behavioural therapy (CBT) that focuses on psychological flexibility and behaviour change, provided a significant reduction in self-reported depression and anxiety among patients participating in a pain rehabilitation programme.

14. Jun. 2017

BIOLOGICAL DMARD GUIDELINES ASSOCIATED WITH A REDUCED NEED FOR KNEE AND HIP REPLACEMENTS IN RA PATIENTS

The results of a Danish study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that the incidence of total knee replacements (TKR) carried out on patients with rheumatoid arthritis (RA) started to decrease after the introduction of biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) to national treatment guidelines.

14. Jun. 2017

PREVIOUS BACTERIAL INFECTION INCREASES RISK OF NEWLY-DIAGNOSED SJÖGREN’S SYNDROME

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have shown a link between newly-diagnosed Sjögren’s syndrome (SjS) and previous infection with nontuberculous mycobacteria (NTM).

14. Jun. 2017

NEW TOOLS HELP EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis (SSc).

14. Jun. 2017

NEW IMAGING TECHNIQUE MAY HELP IDENTIFY JOINT INFLAMMATION IN CHILDREN EARLIER AND WITH GREATER CONFIDENCE

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 have confirmed that Fluorescence Optical Imaging (FOI), a technique used to visualise inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis (JIA). FOI was also found to be more effective than US / PD at detecting inflammation in the absence of symptoms and signs.

14. Jun. 2017

NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference should reassure rheumatologists regarding the risk of cancer from the use of biological disease modifying anti-rheumatic drugs (bDMARDs), including anti-TNF treatment, in patients with rheumatoid arthritis (RA).

14. Jun. 2017

NEW CLASS OF DRUG SIGNIFICANTLY REDUCES SPINE FRACTURE RISK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.

14. Jun. 2017

EARLY THERAPEUTIC INTERVENTION FOR PRE-RHEUMATOID ARTHRITIS (PRE-RA) PATIENTS SIGNIFICANTLY REDUCES RISK OF RA

The results of a meta-analysis presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference has demonstrated that early therapeutic intervention in patients with so-called “pre-rheumatoid arthritis” (pre-RA) significantly reduces the risk of the occurrence of rheumatoid arthritis (RA) in these patients at 52 weeks or more.

14. Jun. 2017

CONTINUING ANTI-TNF TREATMENT WITH CZP FOR RA DURING PREGNANCY: NO OR NEGLIGIBLE PLACENTAL TRANSFER

The results of a pharmacokinetic study presented at the Annual European Congress of Rheumatology (EULAR) 2017 showed no or negligible placental transfer of the anti-TNF drug certolizumab pegol (CZP) from mothers to infants during pregnancy.

14. Jun. 2017

BODY FAT AND WAIST SIZE LINKED TO INCREASED RISK OF DEVELOPING RHEUMATOID ARTHRITIS IN WOMEN

The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 showed that, in women, being overweight or obese, as defined by body mass index (BMI*), abdominal obesity and a higher body fat percentage was associated with a higher risk of developing rheumatoid arthritis (RA).

1. Jun. 2017

EULAR launches 'RheumaMap’ in EU Parliament in Brussels

In a meeting of the Interest Group on Rheumatic and Musculoskeletal Diseases (RMDs), the “Research Roadmap to transform the lives of people with Rheumatic and Musculoskeletal Diseases” was launched in the European Parliament.